Premium
Alendronate induced subacute cutaneous lupus erythematosus successfully treated with intravenous immunoglobulin
Author(s) -
Uzuncakmak Tugba Kevser,
Bayazit Samet,
Askin Ozge,
Engin Burhan,
Ugurlu Serdal,
Sar Mehmet,
Serdaroglu Server
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.14477
Subject(s) - medicine , subacute cutaneous lupus erythematosus , terbinafine , dermatology , antibody , serology , systemic lupus erythematosus , lupus erythematosus , immunology , connective tissue disease , disease , autoimmune disease , antifungal , itraconazole
The subacute cutaneous lupus erythematosus (SCLE) is a distinct subtype of lupus erythematosus (LE) representing specific clinical and serological features. Almost 20%‐30% of the cases with SCLE are predicted to associated with medications. Thiazide diuretics, terbinafine, antiepileptic, and proton pump inhibitors are the best‐known drugs to induce drug‐related SCLE. Herein we want to present a 65‐year‐old female with alendronate induced SCLE, resistant to classical therapies, and respond well to intravenous immunoglobulin (IVIG), suggesting that IVIG could be an alternative treatment in patients resistant to classical treatment protocols.